Sixera Pharma AB
556901-4763ActiveSmall biotech developing first treatment for rare Netherton syndrome.
Biopharmaceutical Companysixerapharma.com
Oversikt
- 1–4
- Ansatte
- ≤1t SEK
- Omsetning
- 2012
- Grunnlagt
Beskrivelse
Sixera Pharma is a small biopharmaceutical company established in Stockholm in 2013. The company originated from a project spun out of Swedish Orphan Biovitrum (Sobi) and Arexis. Their core mission is to develop their lead compound, SXR1096, into the first available treatment for Netherton syndrome....
Tagger
B2BHealthcarePharmaceuticals
Nøkkelord
BiotechnologyDrug DevelopmentNetherton Syndrome
AUTHERA AS